Patient and treatment characteristics
| Characteristic . | Data . |
|---|---|
| N | 119 |
| Age, median (range), y | 69 (18-86) |
| Sex | |
| Female | 59 (50) |
| Male | 60 (50) |
| AML setting | |
| Newly diagnosed | 55 (46) |
| r/r | 64 (54) |
| AML subtype | |
| De novo | 63 (53) |
| Therapy related | 23 (19) |
| Secondary | 33 (28) |
| Prior alloHCT | |
| Yes | 16 (13) |
| No | 103 (87) |
| 2017 ELN cytogenetics-molecular risk | |
| Favorable | 13 (11) |
| Intermediate | 34 (29) |
| Adverse | 72 (60) |
| HMA | |
| Azacitidine | 16 (13) |
| Decitabine | 103 (87) |
| 5 d | 49 (48) |
| 10 d | 54 (52) |
| VEN-HMA cycles, median (range) | 3 (1-21) |
| Responders | 4 (1-21) |
| Nonresponders | 2 (1-17) |
| Response to VEN-HMAs | |
| Yes | 68 (57) |
| No | 51 (43) |
| Antifungal prophylaxis | |
| None | 25 (21) |
| Micafungin | 45 (38) |
| Azoles | 49 (41) |
| Posaconazole, n | 25 |
| Isavuconazonium, n | 15 |
| Voriconazole, n | 5 |
| Fluconazole, n | 4 |
| Characteristic . | Data . |
|---|---|
| N | 119 |
| Age, median (range), y | 69 (18-86) |
| Sex | |
| Female | 59 (50) |
| Male | 60 (50) |
| AML setting | |
| Newly diagnosed | 55 (46) |
| r/r | 64 (54) |
| AML subtype | |
| De novo | 63 (53) |
| Therapy related | 23 (19) |
| Secondary | 33 (28) |
| Prior alloHCT | |
| Yes | 16 (13) |
| No | 103 (87) |
| 2017 ELN cytogenetics-molecular risk | |
| Favorable | 13 (11) |
| Intermediate | 34 (29) |
| Adverse | 72 (60) |
| HMA | |
| Azacitidine | 16 (13) |
| Decitabine | 103 (87) |
| 5 d | 49 (48) |
| 10 d | 54 (52) |
| VEN-HMA cycles, median (range) | 3 (1-21) |
| Responders | 4 (1-21) |
| Nonresponders | 2 (1-17) |
| Response to VEN-HMAs | |
| Yes | 68 (57) |
| No | 51 (43) |
| Antifungal prophylaxis | |
| None | 25 (21) |
| Micafungin | 45 (38) |
| Azoles | 49 (41) |
| Posaconazole, n | 25 |
| Isavuconazonium, n | 15 |
| Voriconazole, n | 5 |
| Fluconazole, n | 4 |
Unless otherwise noted, data are n (%).
ELN, European LeukemiaNet.